{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:11:42Z","timestamp":1774483902901,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Public Assistance Hospitals Paris","doi-asserted-by":"publisher","award":["AOM06107"],"award-info":[{"award-number":["AOM06107"]}],"id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002738","name":"Public Assistance Hospitals Paris","doi-asserted-by":"publisher","award":["AOM12209"],"award-info":[{"award-number":["AOM12209"]}],"id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.parkreldis.2025.108017","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T06:53:44Z","timestamp":1756882424000},"page":"108017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparison of tetrabenazine, tiapride and olanzapine in Huntington's disease: a one-year French randomized multicenter study (Neuro-HD)"],"prefix":"10.1016","volume":"140","author":[{"given":"Katia","family":"Youssov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Audureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mie","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Azulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Benatru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Durr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Krystkowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Marelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Tranchant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Simonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Verny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Catherine","family":"Bachoud-L\u00e9vi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.parkreldis.2025.108017_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108017_bib2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"2\u20133","key":"10.1016\/j.parkreldis.2025.108017_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.brainresbull.2006.10.027","article-title":"Comprehensive care in huntington's disease: a physician's perspective","volume":"72","author":"Nance","year":"2007","journal-title":"Brain Res. Bull."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108017_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","article-title":"Symptomatic treatment of huntington disease","volume":"5","author":"Adam","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1016\/j.parkreldis.2025.108017_bib5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a european huntington's disease cohort (REGISTRY)","volume":"85","author":"van Duijn","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2025.108017_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2022.11.004","article-title":"Psychotropic medication use in huntington's disease: a retrospective cohort study","volume":"105","author":"Andriessen","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"10.1016\/j.parkreldis.2025.108017_bib7","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/mdc3.14230","article-title":"Medication use and treatment indications in huntington's disease; analyses from a large cohort","volume":"11","author":"Feleus","year":"2024","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108017_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mds.28855","article-title":"An MDS evidence-based review on treatments for huntington's disease","volume":"37","author":"Ferreira","year":"2022","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108017_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.108017_bib10","first-page":"18","article-title":"Tetrabenazine as anti-chorea therapy in huntington disease: an open-label continuation study. Huntington study Group\/TETRA-HD investigators. BMC neurol. 2009 Dec 18;9:62","volume":"11","author":"Frank","year":"2011","journal-title":"Erratum in: BMC Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108017_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/03007995.2018.1435518","article-title":"Physician perceptions of pharmacologic treatment options for chorea associated with huntington disease in the United States","volume":"34","author":"Sung","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.parkreldis.2025.108017_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1259","article-title":"An international Survey-based algorithm for the pharmacologic treatment of irritability in huntington's disease","volume":"3","author":"Groves","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1016\/j.parkreldis.2025.108017_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3389\/fneur.2019.00710","article-title":"International guidelines for the treatment of huntington's disease","volume":"10","author":"Bachoud-L\u00e9vi","year":"2019","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108017_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085430","article-title":"Effectiveness of anti-psychotics and related drugs in the huntington French-speaking group cohort","volume":"9","author":"D\u00e9sam\u00e9ricq","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.parkreldis.2025.108017_bib15","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/mds.22188","article-title":"A Europe-wide assessment of current medication choices in huntington's disease","volume":"23","author":"Priller","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.108017_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1260","article-title":"An international Survey-based algorithm for the pharmacologic treatment of chorea in huntington's disease","volume":"3","author":"Burgunder","year":"2011","journal-title":"PLoS Curr"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108017_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","article-title":"Pharmacologic approaches to the treatment of huntington's disease","volume":"27","author":"Venuto","year":"2012","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108017_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in huntington's disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108017_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0404.1982.tb03060.x","article-title":"Tiapride in the treatment of Huntington's chorea","volume":"65","author":"Roos","year":"1982","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108017_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/03007998409109601","article-title":"Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea","volume":"9","author":"Deroover","year":"1984","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108017_bib21","first-page":"69","article-title":"Short-term effects of olanzapine in huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2025.108017_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","article-title":"Olanzapine in Huntington's disease","volume":"105","author":"Paleacu","year":"2002","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108017_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","article-title":"Olanzapine for Huntington's disease: an open label study","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108017_bib24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1590\/S0004-282X2004000600030","article-title":"Functional and motor response to low dose olanzapine in huntington's disease: case report","volume":"62","author":"Laks","year":"2004","journal-title":"Arq. Neuropsiquiatr."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.108017_bib25","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.31.10.1333","article-title":"Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs","volume":"31","author":"Shoulson","year":"1981","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108017_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: reliability and consistency","volume":"11","year":"1996","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108017_bib27","first-page":"452","article-title":"Rate of functional decline in huntington's disease","volume":"54","author":"Marder","year":"2000","journal-title":"Huntington Study Group. Neurology"},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108017_bib28","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1212\/WNL.56.8.1052","article-title":"Retest effects and cognitive decline in longitudinal follow-up of patients with early HD","volume":"56","author":"Bachoud-L\u00e9vi","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.108017_bib29","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","article-title":"Motor, cognitive, and functional declines contribute to a single progressive factor in early HD","volume":"89","author":"Schobel","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.parkreldis.2025.108017_bib30","first-page":"1582","article-title":"Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease: the TREND-HD study","volume":"65","year":"2008","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108017_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mdc3.12706","article-title":"Comparing Risperidone and Olanzapine to Tetrabenazine for the Management of Chorea in Huntington Disease: An Analysis from the Enroll-HD Database","volume":"6","author":"Schultz","year":"2018","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108017_bib32","article-title":"Therapeutic interventions for symptomatic treatment in huntington's disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108017_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial","volume":"316","author":"Huntington Study Group","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.parkreldis.2025.108017_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/brainsci7060067","article-title":"Neuropsychiatric burden in huntington's disease","volume":"7","author":"Paoli","year":"2017","journal-title":"Brain Sci."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108017_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.psychres.2011.05.006","article-title":"Suicidal ideation in huntington disease: the role of comorbidity","volume":"188","author":"Wetzel","year":"2011","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.108017_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"Evidence-based guideline: pharmacologic treatment of chorea in huntington disease: report of the guideline development subcommittee of the American academy of neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108017_bib37","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mds.25500","article-title":"Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline","volume":"28","author":"Reilmann","year":"2013","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025007588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025007588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:44:22Z","timestamp":1772883862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802025007588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"alternative-id":["S1353802025007588"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108017","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of tetrabenazine, tiapride and olanzapine in Huntington's disease: a one-year French randomized multicenter study (Neuro-HD)","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108017"}}